$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Several injections of Ofatumumab are effective
2026-02-01 22:25:32
Check Details
Symptoms after 2 years of taking ofatumumab
2026-02-01 22:25:32
Check Details
How to inject Ofatumumab
2026-02-01 22:25:32
Check Details
Lamivudine Dolutegravir Tablets (Dovito) Side Effects
2026-02-01 22:25:32
Check Details
Is Lamivudine Dolutegravir Tablets (Dolutegravir) a blocking drug?
2026-02-01 22:25:32
Check Details
What kind of medicine is Lamivudine Dolutegravir Tablets (Dolutegravir)?
2026-02-01 22:25:32
Check Details
Chinese instructions for Lamivudine Dolutegravir Tablets (Dovito)
2026-02-01 22:25:32
Check Details
How effective is lamivudine dolutegravir tablets (Dovito) in treating AIDS?
2026-02-01 22:25:32
Check Details
How much does lamivudine dolutegravir tablets (Dovito) cost?
2026-02-01 22:25:32
Check Details
What is the blocking success rate of lamivudine dolutegravir tablets (Dovito)?
2026-02-01 22:25:32
Check Details
Is it okay to take lamivudine dolutegravir tablets (Dovito) blocker after high-risk sexual intercourse?
2026-02-01 22:25:32
Check Details
Is it okay to only take lamivudine and dolutegravir tablets (Dovito) for AIDS?
2026-02-01 22:25:32
Check Details
1
2
...
174
175
176
177
178
179
180
...
10221
10222
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Macitentan Guide: Dietary Interactions, Contraindications, and Reproductive Safety Protocols
2
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
3
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
4
Donidalorsen (DAWNZERA®) Side Effects and Safety Management Guide
5
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
6
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
7
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
8
Elafibranor for Primary Biliary Cholangitis: Indication, Dosing, and Safety Overview
9
AbbVie’s TEPKINLY (epcoritamab) Plus R² Granted EU Approval for Relapsed/Refractory Follicular Lymphoma
10
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
11
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
12
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice